Study: Some anticoagulants more cost-effective than warfarin

04/10/2013 | MedPage Today (free registration)

The anticoagulants apixaban, dabigatran and rivaroxaban are more cost-effective than warfarin in the prevention of strokes among patients with nonvalvular atrial fibrillation, according to a study in Stroke: Journal of the American Heart Association. The costs analyzed in the review were associated with clinical events, visits with doctors, medicines, testing and adverse events.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX